Life Sciences Diabetes Management Solutions sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Diabetes Management Solutions
1.1 - About Life Sciences Diabetes Management Solutions sector
Companies in Life Sciences Diabetes Management Solutions develop and commercialize therapeutics, devices, diagnostics, and digital platforms that enable precise glucose monitoring and sustained glycemic control. Offerings range from insulin delivery technologies to connected sensors and evidence-based programs that reduce acute events and long‑term complications. Customers deploy these solutions to standardize diabetes care, integrate data across clinical workflows, and support population‑level management for Type 1 and Type 2 patients.
Typical capabilities include oral and injectable antihyperglycemics, smart insulin pens and pumps, continuous glucose monitoring systems with cloud data services, and closed‑loop automated insulin delivery. Vendors also provide point‑of‑care and laboratory HbA1c, lipid, and microalbumin diagnostics, connected glucometers with test strip supply, digital coaching and remote patient monitoring apps, and clinical decision support integrated with EHRs and payer portals for risk stratification and care plan optimization.
Primary customers include hospitals and health systems, endocrinology and diabetes clinics, and payer and managed care organizations. These solutions drive improved glycemic control and medication adherence, reduce hypoglycemia, DKA, and readmissions, streamline data capture for quality reporting, and lower total cost of care. They also enhance care coordination, enable population health analytics, and support value‑based contracting and reimbursement.
2. Buyers in the Life Sciences Diabetes Management Solutions sector
2.1 Top strategic acquirers of Life Sciences Diabetes Management Solutions companies
Tandem Diabetes Care
HQ: United States
Website
- Description: Provider of insulin delivery and diabetes technology solutions, manufacturing automated insulin delivery systems such as the Tandem Mobi and t:slim X2 pumps with Control-IQ hybrid closed-loop technology, and offering complementary diabetes education, pump training, software updates and benefit programs for effective blood-glucose management in multiple international markets.
- Key Products:
- Tandem Mobi system: Wearable, ultra-compact automated insulin delivery pump utilizing Control-IQ technology to continuously adjust basal insulin, providing personalized glucose control with minimal device footprint
- t: slim X2 insulin pump: Touchscreen insulin pump featuring Control-IQ hybrid closed-loop algorithm that automatically delivers and suspends insulin based on glucose sensor data to ease daily diabetes management
- t: connect Diabetes Management Application: Cloud-based app that syncs pump and glucose data, offering users and clinicians real-time dashboards and reports to monitor trends, adjust therapy, and improve outcomes
- t: simulator Insulin Pump Demo App: Mobile simulation app replicating the t:slim X2 pump interface, enabling prospective users and educators to practice programming and navigation without live insulin delivery.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Life Sciences Diabetes Management Solutions sector
M&A buyer group 1: Diabetes Devices
17 companies
View group →
Description: Companies in the Medical Diabetes Management Devices category design, manufacture, and integrate hardware and software that measure glucose and deliver insulin for people with diabetes. They provide continuous glucose monitoring, smart insulin delivery, and connected data platforms that support clinical decision-making and remote care. The value proposition centers on accuracy, reliability, interoperability, and insights that help providers and patients improve glycemic control while streamlining care workflows and supply management.
DarioHealth
- Type: N/A
- Employees: ●●●●●
- Description: Provider of data-driven digital health solutions for chronic condition management, offering an integrated platform of connected devices, mobile apps and analytics for diabetes, hypertension, weight, behavioral and musculoskeletal care, as well as employer and health-plan programs that improve outcomes and lower costs.
- Key Products:
- Diabetes Management Solution: Smartphone-connected digital therapeutic combining real-time glucose monitoring, personalized coaching, and evidence-based interventions to drive sustained behavior change and improved glycemic control
- Hypertension Management Solution: AI-driven program that pairs connected blood-pressure monitoring with adaptive software and coaching to help users track readings, receive feedback, and lower blood-pressure levels
- Cardiometabolic Suite for Employers: Multi-condition platform offered to employer populations, bundling diabetes, hypertension and related chronic-care programs to generate recurring outcomes-based revenue
- Multi-Condition Digital Therapeutics Platform: Core software infrastructure integrating life-science, behavioral-science and analytics capabilities to rapidly expand into additional chronic conditions and geographic markets.
🔒
🔒
🔒
View all 17 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Life Sciences Diabetes Management Solutions sector
3.1 - Buyout funds in the Life Sciences Diabetes Management Solutions sector
2.2 - Strategic buyer groups for Life Sciences Diabetes Management Solutions sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Life Sciences Diabetes Management Solutions companies
4.2 - Public trading comparable groups for Life Sciences Diabetes Management Solutions sector
Valuation benchmark group 1: Diabetes Care Device Companies
7 companies
View group →
Description: Companies in this public trading comparables group design, manufacture, and market diabetes care devices, including insulin delivery systems and glucose monitoring technologies. Business models blend durable hardware, consumable supplies, and connected software, creating recurring revenue streams. They are comparable for valuation because they target similar end markets, rely on reimbursement-driven adoption, and monetize installed bases through disposables and digital services.
Medtronic
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of medical technology solutions including advanced devices and therapies for various medical conditions, focusing on cardiac care, neurological disorders, diabetes management, and surgical innovations to improve patient outcomes and enhance healthcare delivery.
- Key Products:
- Cardiac devices: Pacemakers and defibrillators for heart rhythm disorders
- Insulin pumps: Advanced systems for diabetes management
- Surgical innovations: Minimally invasive surgical tools and robotics
- Neurostimulation: Implants for pain management and neurological conditions
- Patient monitoring: Advanced monitoring systems for acute care.
🔒
🔒
🔒
View all 7 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →